Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Sanofi's asthma drug amlitelimab shows promise, leading to further trials and exploration of related respiratory treatments.
Sanofi has made strides in its respiratory drug development.
Amlitelimab, an asthma treatment, showed promising results for certain asthma patients, though primary goals were not fully met.
The company plans to move forward with phase 3 trials for amlitelimab and is exploring other drugs, lunsekimig and itepekimab, for broader respiratory conditions including COPD and chronic rhinosinusitis, with new studies starting this year and in 2026.
3 Articles
El medicamento para el asma de Sanofi amlitelimab es prometedor, lo que lleva a más ensayos y exploración de tratamientos respiratorios relacionados.